1-2 of 2
Francesco Forconi, MD PhD FRCPath
Close
Save search
Sort by
Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Free
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Nichola Webster, Surita Dalal, PhD, Kristian Brock, PhD, Francesca Yates, PhD, Chhaya Sankhalpara, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Christopher Fegan, Alison McCaig, MBChB, FRCPath, PhD MRCP, Anna Schuh, MD MRCP, PhD, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Piers Patten, MD PhD, Stephen Devereux, PhD FRCP, FRCPath, MRCPath, MB BS, Adrian Bloor, PhD FRCP, FRCPath, Christopher P Fox, PhD FRCPath, MRCP, MBChB, Francesco Forconi, MD PhD FRCPath, Andrew Rawstron, PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-136960
Published: 2020
Journal Articles

Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia

Free
Zhenghao Chen, Gaspard Cretenet, Beatriz Valle-Argos, Francesco Forconi, MD PhD FRCPath, Arnon P. Kater, MDPhD, Graham Packham, PhD, Eric Eldering, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-142839
Published: 2020